RVU120, a selective CDK8/CDK19 inhibitor, demonstrates efficacy against hormone-independent breast cancer cells in vitro and in vivo

被引：0
|
作者：
Pakulska, Urszula [1 ]
Obacz, Marta [1 ]
Golas, Aniela [1 ]
Mazan, Milena [1 ]
Masiejczyk, Magdalena [1 ]
Stachowicz, Agata [1 ]
Martyka, Justyna [1 ]
Combik, Michal [1 ]
Keska, Kinga [1 ]
Wiklik, Katarzyna [1 ]
Goller, Kristina [1 ]
Adamczyk, Elzbieta [1 ]
Brzozka, Krzysztof [1 ]
Rzymski, Tomasz [1 ]
机构：
[1] Ryvu Therapeut, Krakow, Poland
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2647
引用
收藏
页数：2
相关论文
共 38 条
  • [21] MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
    Zhang, Hanghang
    Huang, Chen
    Gordon, John
    Yu, Sijia
    Morton, George
    Childers, Wayne
    Abou-Gharbia, Magid
    Zhang, Yi
    Jelinek, Jaroslav
    Issa, Jean-Pierre J.
    CLINICAL EPIGENETICS, 2024, 16 (01)
  • [22] MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
    Hanghang Zhang
    Chen Huang
    John Gordon
    Sijia Yu
    George Morton
    Wayne Childers
    Magid Abou-Gharbia
    Yi Zhang
    Jaroslav Jelinek
    Jean-Pierre J. Issa
    Clinical Epigenetics, 16
  • [23] A first-in-class CDK4 inhibitor shows excellent in vitro and in vivo efficacy against ovarian cancer
    Mekonnen, Laychiluh B.
    Zeleke, Solomon
    Lenjisa, Jimma
    Yu, Mingfeng
    Noll, Benjamin
    Heinemann, Gary
    Milne, Robert
    Albrecht, Hugo
    Oehler, Martin K.
    Wang, Shudong
    CANCER RESEARCH, 2018, 78 (13)
  • [24] CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+breast cancer via STAT1 and STAT3.
    Ding, Xiaokai
    Sharko, Amanda C.
    McDermott, Martina S-J
    Ji, Hao
    Chumanevich, Alexander
    Schools, Gary P.
    Mack, Zachary T.
    Pugacheva, Elena
    Tatarskiy, Victor
    Khrustaleva, Anastasia
    Tyakht, Alexander
    Shtutman, Michael
    Chen, Mengqian
    Roninson, Igor
    Broude, Eugenia V.
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Multiomics Analysis Confirms Effective Target Engagement for RVU120-a First-in-Class CDK8/19 Kinase Inhibitor in AML and MR-MDS Patients and Reveals the Mechanism of Action
    Rzymski, Tomasz
    Sroka-Porada, Agnieszka
    Kozakowska, Magdalena
    Glowniak-Kwitek, Urszula
    Bukowska-Strakova, Karolina
    Obacz, Marta
    Littlewood, Peter
    Kus, Kamil
    Goller, Kristina
    Keska, Kinga
    Pakulska, Urszula
    Kozlowska-Tomczyk, Kamila
    Madej, Monika
    Mazan, Milena
    Juszczynski, Przemyslaw
    Zaucha, Jan M.
    Zarzycka, Agnieszka
    Angelosanto, Noemi
    Nogai, Hendrik
    Brzozka, Krzysztof
    BLOOD, 2022, 140 : 5939 - 5940
  • [26] Selective CDK8 inhibitor SEL120-34A alters expression of interferon-related DNA damage resistance signature genes in colorectal cancer
    Rzymski, Tomasz
    Mikula, Michal
    Szajewska-Skuta, Malgorzata
    Zylkiewicz, Eliza
    Sapala, Lukasz
    Dolata, Izabela
    Kitlinska, Agata
    Goryca, Krzysztof
    Grochowska, Aleksandra
    Cabaj, Aleksandra
    Dreas, Agnieszka
    Kucwaj, Katarzyna
    Bialas, Artur
    Radzimierski, Adam
    Golas, Aniela
    Windak, Renata
    Ostrowski, Jerzy
    Brzozka, Krzysztof
    CANCER RESEARCH, 2015, 75
  • [27] SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo
    Konstantinopoulos, Panagiotis A.
    Hodgson, Graeme
    Rajagopal, Nisha
    Johannessen, Liv
    Liu, Joyce F.
    Kirschmeier, Paul T.
    Zhou, Shan
    Cam Anh Tran
    Orlando, David
    Fritz, Christian
    di Tomaso, Emmanuelle
    Matulonis, Ursula A.
    CANCER RESEARCH, 2018, 78 (13)
  • [28] Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance
    Vanessa Maria Knab
    Dagmar Gotthardt
    Klara Klein
    Reinhard Grausenburger
    Gerwin Heller
    Ingeborg Menzl
    Daniela Prinz
    Jana Trifinopoulos
    Julia List
    Daniela Fux
    Agnieszka Witalisz-Siepracka
    Veronika Sexl
    Cell Death & Disease, 12
  • [29] Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance
    Knab, Vanessa Maria
    Gotthardt, Dagmar
    Klein, Klara
    Grausenburger, Reinhard
    Heller, Gerwin
    Menzl, Ingeborg
    Prinz, Daniela
    Trifinopoulos, Jana
    List, Julia
    Fux, Daniela
    Witalisz-Siepracka, Agnieszka
    Sexl, Veronika
    CELL DEATH & DISEASE, 2021, 12 (11)
  • [30] Interference With ER-α Enhances the Therapeutic Efficacy of the Selective CDK Inhibitor Roscovitine Towards ER-Positive Breast Cancer Cells
    Wesierska-Gadek, Jozefa
    Gritsch, David
    Zulehner, Nora
    Komina, Oxana
    Maurer, Margarita
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2011, 112 (04) : 1103 - 1117
1234